Prediction of antibody persistency from antibody titres to natalizumab.
Mult Scler
; 18(10): 1493-9, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-22454098
ABSTRACT
BACKGROUND:
In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.OBJECTIVE:
To use titres of anti-natalizumab antibodies to predict persistency of antibodies. PATIENTS ANDMETHODS:
In 525 consecutive natalizumab treated patients tested for anti-natalizumab antibodies 43 (8.2%) were antibody-positive. Thirty of the antibody-positive patients, who were tested both at three and at six months after treatment start, had antibody titres in blood measured using an extended ELISA method.RESULTS:
Samples from persistently positive patients ( N =18) had higher titre values than samples from transiently positive patients ( N =12). A cut-off value for high titre values was generated, above which patients may discontinue natalizumab therapy after three months. The method had a sensitivity of 0.83, a specificity of 1.00 and a diagnostic accuracy of 0.90.CONCLUSION:
An extended ELISA method for measuring anti-natalizumab antibody titres in multiple sclerosis patients on natalizumab therapy may be used for evaluation of antibody persistence. A test at three months may identify patients with high titres, who should discontinue natalizumab therapy, and patients with transient low-titre antibodies, who may continue natalizumab therapy despite development of antibodies.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Anti-Idiotípicos
/
Anticorpos Monoclonais Humanizados
/
Imunossupressores
/
Esclerose Múltipla
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Mult Scler
Ano de publicação:
2012
Tipo de documento:
Article